Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.
Bhatti
A
A
McGarrity
T J
TJ
Gabbay
R
R
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin